MedPath

Bioequivalence study of Liposomal Amphotericin B 50 mg/vial of Bharat Serums and Vaccines Ltd.

Not Applicable
Completed
Registration Number
CTRI/2023/05/052602
Lead Sponsor
Bharat Serums and Vaccines Ltd
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Healthy male volunteers

Subject who can give written informed consent and communicate effectively

Exclusion Criteria

History of any major surgical procedure

History of any clinically significant medical conditions.

History of chronic alcoholism/ chronic smoking/ drug of abuse.

Subjects with known hypersensitivity to Liposomal Amphotericin B or any of the excipients.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To evaluate the pharmacokinetic profile of Test formulation in comparison to the Reference productTimepoint: PK samples will be collected predose, post dose every hour till 8 hours then every 2 hours till 14 hours. then 4 hourly till 24 hours, then daily till day 7
Secondary Outcome Measures
NameTimeMethod
Safety and tolerability of liposomal amphotericin bTimepoint: Post dose AEs will be captured till the end of study
© Copyright 2025. All Rights Reserved by MedPath